Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT01913951

Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This phase I trial studies the side effects and the best dose of vosaroxin when given together with azacitidine in treating patients with myelodysplastic syndromes. Drugs used in chemotherapy, such as vosaroxin and azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Status: 
Recruiting
Study Date: 
Fri, 11/01/2013 to Thu, 12/01/2016
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: vosaroxin Given IV over 10 minutes on Day 1 and 4 Other Name: voreloxin Drug: Azacitidine Given SC or IV over 15 minutes on days 1-7 Other Names: Vidaza Ladakamycin